Epidemiology and Treatment of Patients with Haemophilia in Austria-Update from the Austrian Haemophilia Registry
Standard
Epidemiology and Treatment of Patients with Haemophilia in Austria-Update from the Austrian Haemophilia Registry. / Rejtő, Judit; Reitter-Pfoertner, Sylvia; Kepa, Sylvia; Feistritzer, Clemens; Grundbichler, Michael; Hörbst, Alexander; Jones, Neil; Muntean, Wolfgang; Neumeister, Peter; Oberbichler, Stefan; Schuster, Gerhard; Schwarz, Rudolf; Thom, Katharina; Zwiauer, Karl; Streif, Werner; Male, Christoph; Pabinger, Ingrid.
In: HAMOSTASEOLOGIE, Vol. 39, No. 3, 08.2019, p. 284-293.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Epidemiology and Treatment of Patients with Haemophilia in Austria-Update from the Austrian Haemophilia Registry
AU - Rejtő, Judit
AU - Reitter-Pfoertner, Sylvia
AU - Kepa, Sylvia
AU - Feistritzer, Clemens
AU - Grundbichler, Michael
AU - Hörbst, Alexander
AU - Jones, Neil
AU - Muntean, Wolfgang
AU - Neumeister, Peter
AU - Oberbichler, Stefan
AU - Schuster, Gerhard
AU - Schwarz, Rudolf
AU - Thom, Katharina
AU - Zwiauer, Karl
AU - Streif, Werner
AU - Male, Christoph
AU - Pabinger, Ingrid
N1 - Georg Thieme Verlag KG Stuttgart · New York.
PY - 2019/8
Y1 - 2019/8
N2 - The Austrian Haemophilia Registry collects epidemiological data on patients with haemophilia, on treatment modalities and potential side effects. The Registry covers more than 85% of the assumed total number of haemophilia patients in Austria. This report summarizes data on 753 patients: 84.3% (635) have haemophilia A and 15.7% (118) have haemophilia B. Patients' median age is 34 years (range: 1-93 years). Of the total cohort, 39.0% (294) patients have severe haemophilia, 11.3% (85) moderate haemophilia, and 49.4% (372) mild haemophilia. Of the patients with severe haemophilia, 38.4% (113) have been infected with hepatitis C virus (HCV) and 12.6% (37) are human immunodeficiency virus (HIV) positive. Overall, 10.6% (67) of patients with haemophilia A and 1.7% (2) of those with haemophilia B have had an inhibitor in their history. Among patients with severe haemophilia, 68.4% (201) receive prophylaxis and 28.6% (84) receive on-demand therapy. There are 65.0% (191) patients with severe haemophilia who are treated with recombinant products. In conclusion, most patients with severe haemophilia receive prophylactic treatment. HCV and HIV infections are still important issues in the Austrian haemophilia population.
AB - The Austrian Haemophilia Registry collects epidemiological data on patients with haemophilia, on treatment modalities and potential side effects. The Registry covers more than 85% of the assumed total number of haemophilia patients in Austria. This report summarizes data on 753 patients: 84.3% (635) have haemophilia A and 15.7% (118) have haemophilia B. Patients' median age is 34 years (range: 1-93 years). Of the total cohort, 39.0% (294) patients have severe haemophilia, 11.3% (85) moderate haemophilia, and 49.4% (372) mild haemophilia. Of the patients with severe haemophilia, 38.4% (113) have been infected with hepatitis C virus (HCV) and 12.6% (37) are human immunodeficiency virus (HIV) positive. Overall, 10.6% (67) of patients with haemophilia A and 1.7% (2) of those with haemophilia B have had an inhibitor in their history. Among patients with severe haemophilia, 68.4% (201) receive prophylaxis and 28.6% (84) receive on-demand therapy. There are 65.0% (191) patients with severe haemophilia who are treated with recombinant products. In conclusion, most patients with severe haemophilia receive prophylactic treatment. HCV and HIV infections are still important issues in the Austrian haemophilia population.
U2 - 10.1055/s-0038-1675354
DO - 10.1055/s-0038-1675354
M3 - SCORING: Journal article
C2 - 30419589
VL - 39
SP - 284
EP - 293
JO - HAMOSTASEOLOGIE
JF - HAMOSTASEOLOGIE
SN - 0720-9355
IS - 3
ER -
